Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding

Pharmacological Research

Volumn 113, Issue , 2016, Pages 484-489

  Pignatelli, Pasquale ^a   Pastori, Daniele ^a   Bartimoccia, Simona ^a   Menichelli, Danilo ^a   Vicario, Tommasa ^a   Nocella, Cristina ^a   Carnevale, Roberto ^a   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti Xa non vitamin k oral anticoagulant; Atrial fibrillation; Glycoprotein VI; Platelet inhibitor; Thromboxane; Warfarin

Indexed keywords

11 DEHYDRO THROMBOXANE; APIXABAN; CREATININE; GLYCOPROTEIN VI; RIVAROXABAN; THROMBOXANE; UNCLASSIFIED DRUG; WARFARIN; 11-DEHYDRO-THROMBOXANE B2; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOGEN RECEPTOR; PLATELET MEMBRANE GLYCOPROTEIN VI; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THROMBOXANE B2;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; URINARY EXCRETION; AGED; ANALOGS AND DERIVATIVES; DRUG EFFECTS; METABOLISM; RISK FACTOR; THROMBOCYTE; URINE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD PLATELETS; CROSS-SECTIONAL STUDIES; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; PYRAZOLES; PYRIDONES; RISK FACTORS; RIVAROXABAN; THROMBOXANE B2; WARFARIN;

EID: 84989172629     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.09.035     Document Type: Article

References (25)

1. [1] Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:8 (1991), 983–988.
2. [2] Soliman, E.Z., Safford, M.M., Muntner, P., Khodneva, Y., Dawood, F.Z., Zakai, N.A., Thacker, E.L., Judd, S., Howard, V.J., Howard, G., Herrington, D.M., Cushman, M., Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 174:1 (2014), 107–114.
3. [3] Pastori, D., Pignatelli, P., Angelico, F., Farcomeni, A., Del Ben, M., Vicario, T., Bucci, T., Raparelli, V., Cangemi, R., Tanzilli, G., Lip, G.Y., Violi, F., Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest 147:6 (2015), 1644–1650.
4. [4] Tanner, R.M., Baber, U., Carson, A.P., Voeks, J., Brown, T.M., Soliman, E.Z., Howard, V.J., Muntner, P., Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am. J. Cardiol. 108:2 (2011), 227–232.
5. [5] Violi, F., Pignatelli, P., Platelet NOX, a novel target for anti-thrombotic treatment. Thromb. Haemost. 111:5 (2014), 817–823.
6. [6] Pastori, D., Carnevale, R., Bartimoccia, S., Nocella, C., Tanzilli, G., Cangemi, R., Vicario, T., Catena, M., Violi, F., Pignatelli, P., Does mediterranean diet reduce cardiovascular events and oxidative stress in atrial fibrillation?. Antioxid. Redox Signaling 23:8 (2015), 682–687.
7. [7] Hansen, M.L., Sorensen, R., Clausen, M.T., Fog-Petersen, M.L., Raunso, J., Gadsboll, N., Gislason, G.H., Folke, F., Andersen, S.S., Schramm, T.K., Abildstrom, S.Z., Poulsen, H.E., Kober, L., Torp-Pedersen, C., Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch. Intern. Med. 170:16 (2010), 1433–1441.
8. [8] Al-Tamimi, M., Arthur, J.F., Gardiner, E., Andrews, R.K., Focusing on plasma glycoprotein VI. Thromb. Haemost. 107:4 (2012), 648–655.
9. [9] Al-Tamimi, M., Grigoriadis, G., Tran, H., Paul, E., Servadei, P., Berndt, M.C., Gardiner, E.E., Andrews, R.K., Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 117:14 (2011), 3912–3920.
10. [10] Camm, A.J., Lip, G.Y., DeCaterina, R., Savelieva, I., Atar, D., Hohnloser, S.H., Hindricks, G., Kirchhof, P., E.S.C.C.f.P. Guidelines, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33:21 (2012), 2719–2747.
11. [11] Mancia, G., Fagard, R., Narkiewicz, K., Redan, J., Zanchetti, A., Bohm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., Galderisi, M., Grobbee, D.E., Jaarsma, T., Kirchof, P., Kjeldsen, S.E., Laurent, S., Manolis, A.J., Nilsson, P.M., Ruilope, L.M., Schmieder, R.E., Sirnes, P.A., Sleight, P., Viigimaa, M., Waeber, B., Zannad, F., List of authors Task Force, 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertens. 31:10 (2013), 1925–1938.
12. [12] M. Authors/Task Force, Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H.P., Huikuri, H., Marre, M., Marx, N., Mellbin, L., Ostergren, J., Patrono, C., Seferovic, P., Uva, M.S., Taskinen, M.R., Tendera, M., Tuomilehto, J., Valensi, P., Zamorano, J.L., Guidelines, Zamorano, J.L., Achenbach, S., Baumgartner, H., Bax, J.J., Bueno, H., Dean, V., Deaton, C., Erol, C., Fagard, R., Ferrari, R., Hasdai, D., Hoes, A.W., Kirchhof, P., Knuuti, J., Kolh, P., Lancellotti, P., Linhart, A., Nihoyannopoulos, P., Piepoli, M.F., Ponikowski, P., Sirnes, P.A., Tamargo, J.L., Tendera, M., Torbicki, A., Wijns, W., Windecker, S., Document, R., DeBacker, G., Sirnes, P.A., Ezquerra, E.A., Avogaro, A., Badimon, L., Baranova, E., Baumgartner, H., Betteridge, J., Ceriello, A., Fagard, R., Funck-Brentano, C., Gulba, D.C., Hasdai, D., Hoes, A.W., Kjekshus, P., Knuuti, J., Kolh, P., Lev, E., Mueller, C., Neyses, L., Nilsson, P.M., Perk, J., Ponikowski, P., Reiner, Z., Sattar, N., Schachinger, V., Scheen, A., Schirmer, H., Stromberg, A., Sudzhaeva, S., Tamargo, J.L., Viigimaa, M., Vlachopoulos, C., Xuereb, R.G., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 34:39 (2013), 3035–3087.
13. [13] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M.A., Jaarsma, T., Kober, L., Lip, G.Y., Maggioni, A.P., Parkhomenko, A., Pieske, B.M., Popescu, B.A., Ronnevik, P.K., Rutten, F.H., Schwitter, J., Seferovic, P., Stepinska, J., Trindade, P.T., Voors, A.A., Zannad, F., Zeiher, A., Task Force for the, A. Treatment of, C. Chronic Heart Failure of the European Society of, Bax, J.J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B.A., Reiner, Z., Sechtem, U., Sirnes, P.A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., McDonagh, T., Sechtem, U., Bonet, L.A., Avraamides, P., BenLamin, H.A., Brignole, M., Coca, A., Cowburn, P., Dargie, H., Elliott, P., Flachskampf, F.A., Guida, G.F., Hardman, S., Iung, B., Merkely, B., Mueller, C., Nanas, J.N., Nielsen, O.W., Orn, S., Parissis, J.T., Ponikowski, P., E.S.C.C.f.P. Guidelines, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14:8 (2012), 803–869.
14. [14] Krotz, F., Sohn, H.Y., Gloe, T., Zahler, S., Riexinger, T., Schiele, T.M., Becker, B.F., Theisen, K., Klauss, V., Pohl, U., NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100:3 (2002), 917–924.
15. [15] Pignatelli, P., Carnevale, R., Di Santo, S., Bartimoccia, S., Sanguigni, V., Lenti, L., Finocchi, A., Mendolicchio, L., Soresina, A.R., Plebani, A., Violi, F., Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler. Thromb. Vasc. Biol. 31:2 (2011), 423–434.
16. [16] Testa, S., Tripodi, A., Legnani, C., Pengo, V., Abbate, R., Dellanoce, C., Carraro, P., Salomone, L., Paniccia, R., Paoletti, O., Poli, D., Palareti, G., Register, S.T.-L., Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb. Res. 137 (2016), 178–183.
17. [17] Lorenzoni, R., Lazzerini, G., Cocci, F., De Caterina, R., Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am. Heart J., 148(1), 2004, e6.
18. [18] Vesterqvist, O., Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans. Scand. J. Clin. Lab. Invest. 48:5 (1988), 401–407.
19. [19] Vazzana, N., Santilli, F., Lattanzio, S., Liani, M., Giacci, L., Del Rosso, G., Salvati, F., Boccatonda, A., Ferroni, P., Davi, G., Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease. Eur. J. Intern. Med. 33 (2016), 74–80.
20. [20] Polzin, A., Dannenberg, L., Sansone, R., Levkau, B., Kelm, M., Hohlfeld, T., Zeus, T., Antiplatelet effects of aspirin in chronic kidney disease patients. J. Thromb. Haemost. 14:2 (2016), 375–380.
21. [21] Pastori, D., Pignatelli, P., Perticone, F., Sciacqua, A., Carnevale, R., Farcomeni, A., Basili, S., Corazza, G.R., Davi, G., Lip, G.Y., Violi, F., A.s. Group, Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. Int. J. Cardiol. 223 (2016), 619–624.
22. [22] Koudstaal, P.J., Ciabattoni, G., van Gijn, J., Nieuwenhuis, H.K., de Groot, P.G., Sixma, J.J., Patrono, C., Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 24:2 (1993), 219–223.
23. [23] Bahit, M.C., Lopes, R.D., Wojdyla, D.M., Hohnloser, S.H., Alexander, J.H., Lewis, B.S., Aylward, P.E., Verheugt, F.W., Keltai, M., Diaz, R., Hanna, M., Granger, C.B., Wallentin, L., Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int. J. Cardiol. 170:2 (2013), 215–220.
24. [24] Kirchhof, P., Ammentorp, B., Darius, H., DeCaterina, R., LeHeuzey, J.Y., Schilling, R.J., Schmitt, J., Zamorano, J.L., Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace 16:1 (2014), 6–14.
25. [25] Lamberts, M., Gislason, G.H., Lip, G.Y., Lassen, J.F., Olesen, J.B., Mikkelsen, A.P., Sorensen, R., Kober, L., Torp-Pedersen, C., Hansen, M.L., Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129:15 (2014), 1577–1585.